CR6731A - Nueva forma de sal y polimorfos - Google Patents

Nueva forma de sal y polimorfos

Info

Publication number
CR6731A
CR6731A CR6731A CR6731A CR6731A CR 6731 A CR6731 A CR 6731A CR 6731 A CR6731 A CR 6731A CR 6731 A CR6731 A CR 6731A CR 6731 A CR6731 A CR 6731A
Authority
CR
Costa Rica
Prior art keywords
polymorphes
salt
new form
refers
present
Prior art date
Application number
CR6731A
Other languages
English (en)
Spanish (es)
Inventor
Ann Basford Patricia
Blaise Hodgson Paul
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005200A external-priority patent/GB0005200D0/en
Priority claimed from GB0015900A external-priority patent/GB0015900D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of CR6731A publication Critical patent/CR6731A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CR6731A 2000-03-03 2002-08-19 Nueva forma de sal y polimorfos CR6731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0005200A GB0005200D0 (en) 2000-03-03 2000-03-03 New salt form
GB0015900A GB0015900D0 (en) 2000-06-28 2000-06-28 New salt form

Publications (1)

Publication Number Publication Date
CR6731A true CR6731A (es) 2004-03-11

Family

ID=26243792

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6731A CR6731A (es) 2000-03-03 2002-08-19 Nueva forma de sal y polimorfos

Country Status (40)

Country Link
US (1) US6683085B2 (ko)
EP (1) EP1268468B1 (ko)
JP (1) JP3857919B2 (ko)
KR (1) KR100496089B1 (ko)
CN (1) CN1214029C (ko)
AP (1) AP2002002611A0 (ko)
AR (1) AR029482A1 (ko)
AT (1) ATE253570T1 (ko)
AU (1) AU779118B2 (ko)
BG (1) BG106869A (ko)
BR (1) BR0108910A (ko)
CA (1) CA2398963C (ko)
CR (1) CR6731A (ko)
CZ (1) CZ20022858A3 (ko)
DE (1) DE60101157T2 (ko)
DK (1) DK1268468T3 (ko)
EA (1) EA004748B1 (ko)
EE (1) EE200200496A (ko)
ES (1) ES2208565T3 (ko)
GE (1) GEP20043364B (ko)
HK (1) HK1053655A1 (ko)
HN (1) HN2001000036A (ko)
HR (1) HRP20020718A2 (ko)
HU (1) HUP0300006A3 (ko)
IL (1) IL150634A0 (ko)
IS (1) IS6441A (ko)
MA (1) MA26876A1 (ko)
MX (1) MXPA02008665A (ko)
NO (1) NO20024195L (ko)
NZ (1) NZ519672A (ko)
OA (1) OA12186A (ko)
PE (1) PE20011225A1 (ko)
PL (1) PL365070A1 (ko)
PT (1) PT1268468E (ko)
SI (1) SI1268468T1 (ko)
SK (1) SK12282002A3 (ko)
TN (1) TNSN01034A1 (ko)
TR (1) TR200302130T4 (ko)
UA (1) UA72311C2 (ko)
WO (1) WO2001064672A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
DE10223913A1 (de) * 2002-05-29 2003-12-11 Bayer Cropscience Ag Verfahren zur Herstellung spezifischer Kristallmodifikationen polymorpher Substanzen
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914114A (en) 1984-05-28 1990-04-03 Merck Patent Gesellschaft Mit Breschrankter Haftung 3-[4-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)butyl]-5-hydroxy-indole methanesulfonate having sedating and anti-parkinsonism properties
EP0281608B1 (de) * 1986-09-16 1990-07-11 MERCK PATENT GmbH Hydroxyindolderivat
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CZ20022858A3 (cs) 2003-09-17
WO2001064672A1 (en) 2001-09-07
MA26876A1 (fr) 2004-12-20
PE20011225A1 (es) 2001-12-08
EA004748B1 (ru) 2004-08-26
IS6441A (is) 2002-06-25
HK1053655A1 (en) 2003-10-31
HN2001000036A (es) 2001-07-09
HRP20020718A2 (en) 2004-02-29
HUP0300006A3 (en) 2006-01-30
US20020010188A1 (en) 2002-01-24
AP2002002611A0 (en) 2002-09-30
CN1214029C (zh) 2005-08-10
BR0108910A (pt) 2002-12-24
NO20024195D0 (no) 2002-09-03
CN1432010A (zh) 2003-07-23
AU779118B2 (en) 2005-01-06
DE60101157T2 (de) 2004-09-02
UA72311C2 (uk) 2005-02-15
EP1268468A1 (en) 2003-01-02
KR100496089B1 (ko) 2005-06-17
TNSN01034A1 (fr) 2005-11-10
SI1268468T1 (en) 2004-04-30
US6683085B2 (en) 2004-01-27
EP1268468B1 (en) 2003-11-05
ATE253570T1 (de) 2003-11-15
CA2398963C (en) 2006-10-24
PL365070A1 (en) 2004-12-27
ES2208565T3 (es) 2004-06-16
TR200302130T4 (tr) 2004-01-21
AU3588801A (en) 2001-09-12
DE60101157D1 (de) 2003-12-11
PT1268468E (pt) 2004-01-30
SK12282002A3 (sk) 2003-10-07
NZ519672A (en) 2004-06-25
EE200200496A (et) 2004-02-16
MXPA02008665A (es) 2003-02-24
CA2398963A1 (en) 2001-09-07
JP2003525289A (ja) 2003-08-26
GEP20043364B (en) 2004-03-10
JP3857919B2 (ja) 2006-12-13
AR029482A1 (es) 2003-07-02
EA200200826A1 (ru) 2003-02-27
NO20024195L (no) 2002-09-03
BG106869A (bg) 2002-12-29
IL150634A0 (en) 2003-02-12
OA12186A (en) 2006-05-09
HUP0300006A2 (en) 2003-05-28
DK1268468T3 (da) 2004-02-09
KR20020080463A (ko) 2002-10-23

Similar Documents

Publication Publication Date Title
DE60106954D1 (de) Resorcin-derivate
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
BR9803596A (pt) Derivados do resorcinol.
BRPI0316438C1 (pt) uso de eritropoietina em doenças cardíacas
DK1294353T3 (da) Anvendelse af en (R) -enantiomer af liponsyre i kosmetiske og dermatologiske sammensætninger
DZ3425A1 (fr) Derives de quinolinone en tant qu'inhibiteurs kinases de tyrosine
BR0114059A (pt) Derivados de resorcinol
CR6731A (es) Nueva forma de sal y polimorfos
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
MXPA03005601A (es) Nuevos compuestos y composiciones como inhibidores de catepsina.
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
BR0114912A (pt) Kahalalide f
BR0009211A (pt) Derivados de resorcinol
BR0105563A (pt) Derivados e análogos de galantamina
BR0210912A (pt) Compostos e composições como inibidores de catepsina
YU39201A (sh) Upotreba 1-arilpirazola za pripremanje oralnog sredstva za suzbijanje parazita
DE60112960D1 (de) Kondensierte pyridoindolderivate
UY26426A1 (es) Nuevos compuestos
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR0009194A (pt) Composição do resorcinol
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
ATE303135T1 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-
UY26604A1 (es) Nueva forma de sal y polimorfos
CR6829A (es) Derivados de 2-aminocarbonil-9h-purina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)